New Zealand markets closed

Catalyst Pharmaceuticals, Inc. (CPRX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
16.25-0.02 (-0.12%)
As of 10:53AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.92B
Enterprise value 1.78B
Trailing P/E 25.84
Forward P/E 12.67
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.65
Price/book (mrq)4.95
Enterprise value/revenue 4.48
Enterprise value/EBITDA 14.91

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 3-1.15%
S&P500 52-week change 329.57%
52-week high 318.22
52-week low 311.09
50-day moving average 314.98
200-day moving average 313.93

Share statistics

Avg vol (3-month) 31.51M
Avg vol (10-day) 31.4M
Shares outstanding 5117.86M
Implied shares outstanding 6117.86M
Float 8101.36M
% held by insiders 16.41%
% held by institutions 173.45%
Shares short (15 Mar 2024) 45.83M
Short ratio (15 Mar 2024) 43.79
Short % of float (15 Mar 2024) 46.10%
Short % of shares outstanding (15 Mar 2024) 44.94%
Shares short (prior month 15 Feb 2024) 45.67M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 17.93%
Operating margin (ttm)37.71%

Management effectiveness

Return on assets (ttm)12.83%
Return on equity (ttm)20.75%

Income statement

Revenue (ttm)398.2M
Revenue per share (ttm)3.75
Quarterly revenue growth (yoy)82.00%
Gross profit (ttm)N/A
EBITDA 119.69M
Net income avi to common (ttm)71.41M
Diluted EPS (ttm)0.63
Quarterly earnings growth (yoy)36.80%

Balance sheet

Total cash (mrq)137.64M
Total cash per share (mrq)1.17
Total debt (mrq)3.56M
Total debt/equity (mrq)0.92%
Current ratio (mrq)2.88
Book value per share (mrq)3.62

Cash flow statement

Operating cash flow (ttm)143.6M
Levered free cash flow (ttm)-219.49M